POINT BIOPHARMA GLOBAL INC (PNT)
US7305411099 - Common Stock
We assign a fundamental rating of 5 out of 10 to PNT. PNT was compared to 588 industry peers in the Biotechnology industry. PNT is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. PNT has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
PNT had positive earnings in the past year.
In the past year PNT had a positive cash flow from operations.
1.2 Ratios
With an excellent Return On Assets value of 20.22%, PNT belongs to the best of the industry, outperforming 99.49% of the companies in the same industry.
The Return On Equity of PNT (22.77%) is better than 97.81% of its industry peers.
PNT has a Return On Invested Capital of 18.63%. This is amongst the best in the industry. PNT outperforms 99.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.22% | ||
| ROE | 22.77% | ||
| ROIC | 18.63% |
ROA(3y)-20.26%
ROA(5y)N/A
ROE(3y)-32.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 39.62%, PNT belongs to the best of the industry, outperforming 99.33% of the companies in the same industry.
With an excellent Operating Margin value of 44.22%, PNT belongs to the best of the industry, outperforming 98.99% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 44.22% | ||
| PM (TTM) | 39.62% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PNT has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
PNT has more shares outstanding than it did 1 year ago.
PNT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 16.90 indicates that PNT is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 16.90, PNT belongs to the top of the industry, outperforming 91.23% of the companies in the same industry.
The Debt to FCF ratio of PNT is 0.06, which is an excellent value as it means it would take PNT, only 0.06 years of fcf income to pay off all of its debts.
PNT has a better Debt to FCF ratio (0.06) than 97.30% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that PNT is not too dependend on debt financing.
PNT has a Debt to Equity ratio (0.01) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.06 | ||
| Altman-Z | 16.9 |
ROIC/WACC1.67
WACC11.15%
2.3 Liquidity
A Current Ratio of 9.13 indicates that PNT has no problem at all paying its short term obligations.
PNT's Current ratio of 9.13 is fine compared to the rest of the industry. PNT outperforms 73.52% of its industry peers.
A Quick Ratio of 9.13 indicates that PNT has no problem at all paying its short term obligations.
The Quick ratio of PNT (9.13) is better than 73.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.13 | ||
| Quick Ratio | 9.13 |
3. Growth
3.1 Past
PNT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 195.40%, which is quite impressive.
EPS 1Y (TTM)195.4%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q11.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
Based on estimates for the next years, PNT will show a very strong growth in Earnings Per Share. The EPS will grow by 22.94% on average per year.
PNT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 72.58% yearly.
EPS Next Y9.21%
EPS Next 2Y-2.62%
EPS Next 3Y36.93%
EPS Next 5Y22.94%
Revenue Next Year-14.35%
Revenue Next 2Y21.4%
Revenue Next 3Y112.36%
Revenue Next 5Y72.58%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 15.06, which indicates a correct valuation of PNT.
Based on the Price/Earnings ratio, PNT is valued cheaper than 97.47% of the companies in the same industry.
When comparing the Price/Earnings ratio of PNT to the average of the S&P500 Index (24.67), we can say PNT is valued slightly cheaper.
PNT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.06 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PNT is valued cheaper than 97.98% of the companies in the same industry.
97.64% of the companies in the same industry are more expensive than PNT, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.37 | ||
| EV/EBITDA | 6.16 |
4.3 Compensation for Growth
PNT's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PNT's earnings are expected to grow with 36.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.64
PEG (5Y)N/A
EPS Next 2Y-2.62%
EPS Next 3Y36.93%
5. Dividend
5.1 Amount
No dividends for PNT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
POINT BIOPHARMA GLOBAL INC
NASDAQ:PNT (12/26/2023, 7:10:43 PM)
After market: 12.51 +0.01 (+0.08%)12.5
+0.02 (+0.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.33B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.06 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.64
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.22% | ||
| ROE | 22.77% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 44.22% | ||
| PM (TTM) | 39.62% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.13 | ||
| Quick Ratio | 9.13 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)195.4%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y9.21%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y